文献速递类风湿关节炎

类风湿关节炎孕妇中sFlt-1/PlGF比值:疾病活动度与柳氮磺吡啶的影响

The sFlt-1 to PlGF ratio in pregnant women with rheumatoid arthritis: impact of disease activity and sulfasalazine use.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

本研究基于全国性观察性前瞻性队列,纳入221例妊娠期类风湿关节炎(RA)孕妇,于孕晚期检测sFlt-1与PlGF。结果显示sFlt-1/PlGF比值不受疾病活动度影响,比值≤38对子痫前期有98.1%的阴性预测值,且柳氮磺吡啶(SSZ)使用未改变sFlt-1或PlGF水平。

要点

  • RA孕妇孕晚期sFlt-1/PlGF比值不受疾病活动度影响。
  • sFlt-1/PlGF比值≤38可用于排除子痫前期,阴性预测值98.1%。
  • SSZ使用未显著改变sFlt-1或PlGF水平。

核心结论

  • 在RA孕妇中,sFlt-1/PlGF比值不因疾病活动度而改变,切点≤38可用于排除子痫前期。
  • SSZ使用未影响该人群的sFlt-1或PlGF水平。

研究设计与样本

  • 基于全国性、观察性、前瞻性妊娠期RA女性队列研究,于孕晚期检测sFlt-1和PlGF。
  • 共纳入221例21-42岁女性,中位孕周为30+3周。

主要发现

  • 高、中、低疾病活动度组间sFlt-1和PlGF无差异(P=0.07和P=0.41)。
  • sFlt-1和PlGF与DAS28-CRP评分不相关(r=-0.01和r=-0.05)。
  • sFlt-1/PlGF比值≤38的4例(2%)发生子痫前期,比值>38的3例(43%)发生子痫前期,阴性预测值98.1%。
  • SSZ使用者(n=57)与非使用者(n=164)的sFlt-1和PlGF水平无差异(P=0.91和P=0.11)。

关键数值与推荐

  • sFlt-1/PlGF比值切点≤38用于排除子痫前期,阴性预测值98.1%。

临床怎么用

  • RA孕妇孕晚期可检测sFlt-1/PlGF比值,≤38有助于排除子痫前期。
  • 疾病活动度不影响该比值解读,SSZ使用亦不干扰检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: An elevated sFlt-1/PlGF ratio has been validated as a significant predictor of preeclampsia, but has not been established in women with RA. We explored whether the sFlt-1/PlGFratio could be altered due to disease activity in RA, and could be applied in this population to predict preeclampsia. Since SSZ has been suggested to improve the angiogenic imbalance in preeclampsia, we also aimed to examine whether SSZ could affect sFlt-1 or PlGF levels. METHODS: Making use of a nationwide, observational, prospective cohort study on pregnant women with RA, sFlt-1 and PlGF were measured in the third trimester. A total of 221 women, aged 21-42 years, were included, with a median gestational age of 30 + 3 weeks. RESULTS: No differences in sFlt-1 or PlGF were observed between women with high, intermediate or low disease activity (P = 0.07 and P = 0.41), whereas sFlt-1 and PlGF did not correlate with DAS28-CRP score (r = -0.01 and r = -0.05, respectively). Four (2%) women with a sFlt-1/PlGF ratio ≤38 developed preeclampsia in comparison to three (43%) women with a ratio > 38, corresponding to a negative predictive value of 98.1%. SSZ users (n = 57) did not show altered levels of sFlt-1 or PlGF in comparison to non-SSZ users (n = 164, P = 0.91 and P = 0.11). CONCLUSION: Our study shows that in pregnant women with RA, the sFlt-1/PlGF ratio is not altered due to disease activity and a cut-off ≤38 can be used to exclude preeclampsia. Additionally, SSZ use did not affect sFlt-1 or PlGF levels in this population.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Neuman RI, Smeele HTW, Jan Danser AH, et al. The sFlt-1 to PlGF ratio in pregnant women with rheumatoid arthritis: impact of disease activity and sulfasalazine use. Rheumatology (Oxford). 2022. PMID: 33890628. doi:10.1093/rheumatology/keab372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。